{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:07:46Z","timestamp":1792757266374,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies targeting amyloid-\u03b2 are the first approved disease-modifying treatment for Alzheimer\u2019s disease. While amyloid-targeting therapies mitigate the progression of cognitive decline in early-stage Alzheimer\u2019s disease, they are associated with amyloid-related imaging abnormalities (ARIA), an imaging phenomenon presenting as cerebral edema\/effusion and\/or hemorrhage. Redistribution of parenchymal amyloid-\u03b2 to perivascular drainage pathways and direct antibody-amyloid interactions within the cerebral vasculature are considered key players in ARIA pathophysiology by promoting inflammation and vascular disruption, thus mirroring hallmarks of inflammatory cerebral amyloid angiopathy. Although ARIA is commonly regarded as an undesired side effect of amyloid-targeting therapies, its association with amyloid-\u03b2 clearance from the brain opens up the possibility of an alternative interpretation as a physiological reaction to target engagement of anti-amyloid antibodies.<\/jats:p>\n                  <jats:p>Understanding risk factors that promote the occurrence of ARIA and its transformation from asymptomatic imaging phenomenon to its serious and severe form are of great importance to clinical practice. ARIA risk and severity are influenced by apolipoprotein E4 status, microvascular damage, and cerebral amyloid angiopathy, but may be further modulated by antibody binding preferences and comorbidities such as arterial hypertension and ischemic strokes. Identifying individual risk profiles based on deeper insights into pathophysiological pathways may improve patient safety and lead to personalized treatment concepts in Alzheimer\u2019s disease.<\/jats:p>\n                  <jats:p>In this review, we provide a comprehensive summary of ARIA pathophysiology, highlight important risk factors and discuss their relevance in clinical risk management.<\/jats:p>","DOI":"10.1186\/s13195-026-02022-7","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:50:14Z","timestamp":1774673414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Amyloid-related imaging abnormalities (ARIA) in Alzheimer\u2019s disease: from pathophysiology to individualized risk assessment"],"prefix":"10.1186","volume":"18","author":[{"given":"Jonathan","family":"Merkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg B.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"2022_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7:33. https:\/\/doi.org\/10.1038\/s41572-021-00269-y.","journal-title":"Nat Rev Dis Primers"},{"key":"2022_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21:306\u201318. https:\/\/doi.org\/10.1038\/s41573-022-00391-w.","journal-title":"Nat Rev Drug Discov"},{"key":"2022_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in Early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"2022_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"2022_CR5","doi-asserted-by":"publisher","unstructured":"Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs Context. 2021;10. https:\/\/doi.org\/10.7573\/dic.2021-7-3.","DOI":"10.7573\/dic.2021-7-3"},{"key":"2022_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14:191. https:\/\/doi.org\/10.1186\/s13195-022-01124-2.","journal-title":"Alzheimers Res Ther"},{"key":"2022_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9:211\u201320. https:\/\/doi.org\/10.14283\/jpad.2022.21.","journal-title":"J Prev Alzheimers Dis"},{"key":"2022_CR8","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324. https:\/\/doi.org\/10.1093\/brain\/awad188.","journal-title":"Brain"},{"key":"2022_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig LS, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16:105. https:\/\/doi.org\/10.1186\/s13195-024-01441-8.","journal-title":"Alzheimers Res Ther"},{"key":"2022_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0065","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, et al. Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol. 2025. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0065.","journal-title":"JAMA Neurol"},{"key":"2022_CR11","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784. https:\/\/doi.org\/10.3389\/fnins.2024.1326784.","journal-title":"Front Neurosci"},{"key":"2022_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362\u201377. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"J Prev Alzheimers Dis"},{"key":"2022_CR13","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, et al. Donanemab: Appropriate use recommendations. J Prev Alzheimers Dis. 2025;12:100150. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150.","journal-title":"J Prev Alzheimers Dis"},{"key":"2022_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-336597","author":"CJ Mummery","year":"2025","unstructured":"Mummery CJ, et al. Lecanemab appropriate use recommendations for clinical practice in the UK. J Neurol Neurosurg Psychiatry. 2025. https:\/\/doi.org\/10.1136\/jnnp-2025-336597.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022_CR15","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova E, et al. Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease. Nat Commun. 2023;14:8220. https:\/\/doi.org\/10.1038\/s41467-023-43933-5.","journal-title":"Nat Commun"},{"key":"2022_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, et al. Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for Stroke. N Engl J Med. 2023;388:478\u20139. https:\/\/doi.org\/10.1056\/NEJMc2215148.","journal-title":"N Engl J Med"},{"key":"2022_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16:30\u201342. https:\/\/doi.org\/10.1038\/s41582-019-0281-2.","journal-title":"Nat Rev Neurol"},{"key":"2022_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8.","journal-title":"Alzheimers Res Ther"},{"key":"2022_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","volume":"21","author":"SM Greenberg","year":"2025","unstructured":"Greenberg SM, Bax F, van Veluw SJ. Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms. Nat Rev Neurol. 2025;21:193\u2013203. https:\/\/doi.org\/10.1038\/s41582-024-01053-8.","journal-title":"Nat Rev Neurol"},{"key":"2022_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, et al. Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2024;19:77. https:\/\/doi.org\/10.1186\/s13024-024-00758-0.","journal-title":"Mol Neurodegener"},{"key":"2022_CR21","doi-asserted-by":"publisher","first-page":"10868","DOI":"10.1038\/s41598-024-61691-2","volume":"14","author":"L S\u00f6derberg","year":"2024","unstructured":"S\u00f6derberg L, et al. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Sci Rep. 2024;14:10868. https:\/\/doi.org\/10.1038\/s41598-024-61691-2.","journal-title":"Sci Rep"},{"key":"2022_CR22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/s1474-4422(25)00313-8","volume":"24","author":"BDC Boon","year":"2025","unstructured":"Boon BDC, et al. Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study. Lancet Neurol. 2025;24:931\u201344. https:\/\/doi.org\/10.1016\/s1474-4422(25)00313-8.","journal-title":"Lancet Neurol"},{"key":"2022_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3988\/jcn.2022.0493","volume":"19","author":"A de Souza","year":"2023","unstructured":"de Souza A, Tasker K. Inflammatory cerebral amyloid angiopathy: a broad clinical spectrum. J Clin Neurol. 2023;19:230\u201341. https:\/\/doi.org\/10.3988\/jcn.2022.0493.","journal-title":"J Clin Neurol"},{"key":"2022_CR24","doi-asserted-by":"publisher","first-page":"1219025","DOI":"10.3389\/fnins.2023.1219025","volume":"17","author":"B Storti","year":"2023","unstructured":"Storti B, et al. Rare forms of cerebral amyloid angiopathy: pathogenesis, biological and clinical features of CAA-ri and iCAA. Front Neurosci. 2023;17:1219025. https:\/\/doi.org\/10.3389\/fnins.2023.1219025.","journal-title":"Front Neurosci"},{"key":"2022_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.2214\/ajr.22.28461","volume":"220","author":"M Roytman","year":"2023","unstructured":"Roytman M, et al. Amyloid-related imaging abnormalities: an update. AJR Am J Roentgenol. 2023;220:562\u201374. https:\/\/doi.org\/10.2214\/ajr.22.28461.","journal-title":"AJR Am J Roentgenol"},{"key":"2022_CR26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/brain\/awad005","volume":"146","author":"R Perneczky","year":"2023","unstructured":"Perneczky R, et al. Anti-amyloid antibody therapies in Alzheimer\u2019s disease. Brain. 2023;146:842\u20139. https:\/\/doi.org\/10.1093\/brain\/awad005.","journal-title":"Brain"},{"key":"2022_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79:1113\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2909.","journal-title":"JAMA Neurol"},{"key":"2022_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1312889.","journal-title":"N Engl J Med"},{"key":"2022_CR29","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1002\/alz.70062","volume":"21","author":"H Wang","year":"2025","unstructured":"Wang H, et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimers Dement. 2025;21:e70062. https:\/\/doi.org\/10.1002\/alz.70062.","journal-title":"Alzheimers Dement"},{"key":"2022_CR30","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/psp4.13224","volume":"13","author":"O Majid","year":"2024","unstructured":"Majid O, et al. Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer\u2019s disease. CPT Pharmacometrics Syst Pharmacol. 2024;13:2111\u201323. https:\/\/doi.org\/10.1002\/psp4.13224.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2022_CR31","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ, et al. Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N Engl J Med. 2023;389:1862\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2304430.","journal-title":"N Engl J Med"},{"key":"2022_CR32","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"key":"2022_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30.","journal-title":"J Prev Alzheimers Dis"},{"key":"2022_CR34","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.tjpad.2025.100094","volume":"12","author":"N Villain","year":"2025","unstructured":"Villain N, et al. Lecanemab for early Alzheimer\u2019s disease: appropriate use recommendations from the French federation of memory clinics. J Prev Alzheimers Dis. 2025;12:100094. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100094.","journal-title":"J Prev Alzheimers Dis"},{"key":"2022_CR35","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/s41593-024-01669-5","volume":"27","author":"S Narasimhan","year":"2024","unstructured":"Narasimhan S, et al. Apolipoprotein E in Alzheimer\u2019s disease trajectories and the next-generation clinical care pathway. Nat Neurosci. 2024;27:1236\u201352. https:\/\/doi.org\/10.1038\/s41593-024-01669-5.","journal-title":"Nat Neurosci"},{"key":"2022_CR36","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.neuron.2022.03.004","volume":"110","author":"YA Martens","year":"2022","unstructured":"Martens YA, et al. ApoE Cascade Hypothesis in the pathogenesis of Alzheimer\u2019s disease and related dementias. Neuron. 2022;110:1304\u201317. https:\/\/doi.org\/10.1016\/j.neuron.2022.03.004.","journal-title":"Neuron"},{"key":"2022_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/s1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20:68\u201380. https:\/\/doi.org\/10.1016\/s1474-4422(20)30412-9.","journal-title":"Lancet Neurol"},{"key":"2022_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin AC, et al. ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022;17:72. https:\/\/doi.org\/10.1186\/s13024-022-00574-4.","journal-title":"Mol Neurodegener"},{"key":"2022_CR39","doi-asserted-by":"publisher","first-page":"1412006","DOI":"10.3389\/fnagi.2024.1412006","volume":"16","author":"KE Foley","year":"2024","unstructured":"Foley KE, Wilcock DM. Three major effects of APOE(\u03b54) on A\u03b2 immunotherapy induced ARIA. Front Aging Neurosci. 2024;16:1412006. https:\/\/doi.org\/10.3389\/fnagi.2024.1412006.","journal-title":"Front Aging Neurosci"},{"key":"2022_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71\u20136. https:\/\/doi.org\/10.1038\/s41586-020-2247-3.","journal-title":"Nature"},{"key":"2022_CR41","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1093\/brain\/awab478","volume":"145","author":"RJ Jackson","year":"2022","unstructured":"Jackson RJ, et al. APOE4 derived from astrocytes leads to blood-brain barrier impairment. Brain. 2022;145:3582\u201393. https:\/\/doi.org\/10.1093\/brain\/awab478.","journal-title":"Brain"},{"key":"2022_CR42","doi-asserted-by":"publisher","first-page":"8615","DOI":"10.1002\/alz.14302","volume":"20","author":"ET Reas","year":"2024","unstructured":"Reas ET, et al. APOE ?4-related blood-brain barrier breakdown is associated with microstructural abnormalities. Alzheimers Dement. 2024;20:8615\u201324. https:\/\/doi.org\/10.1002\/alz.14302.","journal-title":"Alzheimers Dement"},{"key":"2022_CR43","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41590-023-01627-6","volume":"24","author":"Z Yin","year":"2023","unstructured":"Yin Z, et al. APOE4 impairs the microglial response in Alzheimer\u2019s disease by inducing TGF\u03b2-mediated checkpoints. Nat Immunol. 2023;24:1839\u201353. https:\/\/doi.org\/10.1038\/s41590-023-01627-6.","journal-title":"Nat Immunol"},{"key":"2022_CR44","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.smim.2022.101594","volume":"59","author":"S Parhizkar","year":"2022","unstructured":"Parhizkar S, Holtzman DM. APOE mediated neuroinflammation and neurodegeneration in Alzheimer\u2019s disease. Semin Immunol. 2022;59:101594. https:\/\/doi.org\/10.1016\/j.smim.2022.101594.","journal-title":"Semin Immunol"},{"key":"2022_CR45","doi-asserted-by":"publisher","first-page":"eadd1236","DOI":"10.1126\/science.add1236","volume":"379","author":"DO Seo","year":"2023","unstructured":"Seo DO, et al. ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy. Science. 2023;379:eadd1236. https:\/\/doi.org\/10.1126\/science.add1236.","journal-title":"Science"},{"key":"2022_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-023-00640-5","volume":"18","author":"Y Inoue","year":"2023","unstructured":"Inoue Y, Shue F, Bu G, Kanekiyo T. Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer\u2019s disease. Mol Neurodegener. 2023;18:46. https:\/\/doi.org\/10.1186\/s13024-023-00640-5.","journal-title":"Mol Neurodegener"},{"key":"2022_CR47","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.14283\/jpad.2024.159","volume":"11","author":"LBE Shields","year":"2024","unstructured":"Shields LBE, et al. Initial experience with Lecanemab and lessons learned in 71 patients in a regional medical center. J Prev Alzheimers Dis. 2024;11:1549\u201362. https:\/\/doi.org\/10.14283\/jpad.2024.159.","journal-title":"J Prev Alzheimers Dis"},{"key":"2022_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","volume":"46","author":"PM Cogswell","year":"2025","unstructured":"Cogswell PM, et al. Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol. 2025;46:24\u201332. https:\/\/doi.org\/10.3174\/ajnr.A8469.","journal-title":"AJNR Am J Neuroradiol"},{"key":"2022_CR49","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm HP, et al. Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs. 2023;15:2261509. https:\/\/doi.org\/10.1080\/19420862.2023.2261509.","journal-title":"MAbs"},{"key":"2022_CR50","unstructured":"https:\/\/www.alzforum.org\/news\/conference-coverage\/unlocking-blood-brain-barrier-boosts-immunotherapy-efficacy-lowers-aria. Accessed 21 October 2025."},{"key":"2022_CR51","unstructured":"https:\/\/www.alzforum.org\/news\/conference-coverage\/fast-plaque-clearance-little-aria-so-teases-trontinemab-adpd-2024. Accessed 21 October 2025."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02022-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02022-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02022-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:02:07Z","timestamp":1781643727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02022-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02022-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.M. has no competing interests to declare. R.P. has received honoraria for advisory boards and speaker engagements from Roche, Eisai, Eli Lilly, Biogen, Janssen-Cilag, AstraZeneca, Schwabe, Grifols, Novo Nordisk, and Tabuk. R.P. is a member of the Steering Committee of the German Network of Memory Clinics. F.J. has received consulting fees, honoraria for advisory boards, speaker engagements, and expert testimony from Eisai, Eli Lilly, Roche, Novo Nordisk, and AC Immune. F.J. has received institutional grants from Roche Pharma. F.J. is chairman of the EADC and board member of the German Network of Memory Clinics and InRAD. L.F. has received consulting fees from Avanex, Biogen, BioVie, Bristol-Myers Squibb, Charles-River Ass., Eli Lilly, Eisai, GE Healthcare, Grifols, Janssen-Cilag, Janssen Research, Neurimmune, Noselab, NovoNordisk, Roche, TauRX, and Schwabe. L.F. has received honoraria for advisory boards, speaker engagements, and expert testimony from Eli Lilly, Eisai, DerCampus, Medscape, Medfora, FOMF, NovoNordisk, Roche, Schwabe, Neuroscios, ReMynd, Otsuka\/Avanir, and Vivoryon. L.F. has received institutional grants from Hoffmann-La Roche. L.F. is a board member of the German Society of Psychiatry, Psychotherapy and Nervous Diseases, the European Alzheimer Disease Consortium, the German Network of Memory Clinics, Alzheimer Europe, and Alzheimer Society Baden-W\u00fcrttemberg. O.J. has received honoraria for speaker engagements from Stryker GmbH and Philips. S.P. has received honoraria for speaker engagements from Bayer and Stryker GmbH. D.B. is the current president of the German Society of Neurology. J.B.S. has received consulting fees, honoraria for advisory boards and speaker engagements from Biogen, Eli Lilly, Reata, and Eisai. J.B.S. has received institutional grants from Biogen, Eli Lilly, and Eisai. J.B.S. is a board member of the German Network of Memory Clinics and speaker of the Commission \u201cDementia\u201d of the German Society of Neurology. T.B. has received consulting fees, honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, BMS, Pfizer, Novo Nordisk. T.B. is a member of the Steering Committee of the German Network of Memory Clinics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}